Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00532324
Other study ID # 2007-13145(CMH)/2623-001(NU)
Secondary ID
Status Recruiting
Phase N/A
First received September 19, 2007
Last updated March 10, 2011
Start date January 2008
Est. completion date January 2010

Study information

Verified date April 2009
Source Ann & Robert H Lurie Children's Hospital of Chicago
Contact Tina Q Tan, M.D.
Phone 773-880-4187
Email titan@childrensmemorial.org
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

Background:

Community acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) is an emerging pathogen of the 21st century whose incidence as a cause of local and invasive infections has significantly increased, especially in previously healthy term and near term newborns. The etiology of the increasing incidence of infection in previously healthy term and near-term newborns remains unclear.

Hypothesis:

1. The incidence of previously healthy newborns infected with CA-MRSA skin & soft tissue (SSTI) and invasive infections is higher in those born to mothers colonized with CA-MRSA.

2. Pregnant women colonized with CA-MRSA are at higher risk for post-partum infection with this organism.

Specific Aims:

1. To determine the incidence of nasal and vaginal colonization with CA-MRSA in pregnant women and determine the genetic similarities of these strains.

2. To study CA-MRSA transmission dynamics and evaluate the incidence of SSTI and invasive infections in newborns born to S. aureus colonized mothers.

3. To study the efficacy of attempted decolonization in CA-MRSA colonized mothers in decreasing the incidence of transmission and development of SSTI and invasive infections in their infants during the first month of life.

Potential Impact:

Understanding the epidemiology of the transmission dynamics of CA-MRSA in previously healthy newborns will provide important information to support the development of strategies aimed at the interruption of transmission and prevention of infection caused by CA-MRSA in newborns, as well as in pregnant women. This will also allow for the development of infection control strategies to prevent the spread of this organism among post-partum units and nurseries.


Description:

Background:

Community acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) is an emerging pathogen of the 21st century whose incidence as a cause of local and invasive infections has significantly increased, especially in previously healthy term and near term neonates where it may be associated with high morbidity and mortality(1, 2, 3). The etiology for this increase remains unclear, but may be a consequence of perinatal or postnatal acquisition via maternal transmission through skin, breast milk, or vaginal colonization(4).

The major goals of our study are: to determine the incidence of pregnant women who are colonized with CA-MRSA, gain a better understanding of the transmission dynamics of this organism between the mother and the newborn infant, and to develop strategies for the prevention of transmission, spread and infection with this organism in both these populations.

This staged study is a collaborative effort between investigators from the Children's Memorial Hospital Division of Infectious Diseases, Northwestern Memorial Hospital Department of Obstetrics and Gynecology, and the Northwestern Memorial Hospital Division of Infectious Diseases. Collaboration across multiple specialties provides strength to the study by allowing the investigators to address multiple issues that are pertinent to both the care of pregnant mothers and newborn infants in the inpatient and outpatient setting.

Hypothesis:

1. The incidence of previously healthy term and near-term neonates infected with CA-MRSA skin & soft tissue (SSTI) and invasive infections is higher in those born to mothers vaginally and/or nasally colonized with CA-MRSA and, 2. Pregnant women vaginally and/or nasally colonized with CA-MRSA are at higher risk for post-partum infection with this organism.

Specific Aims:

1. To determine the incidence of nasal and vaginal colonization with CA-MRSA in pregnant women and determine the clonality of these strains.

2. To study CA-MRSA transmission dynamics and evaluate the incidence of SSTI and invasive infections in term and near-term newborns born to S. aureus vaginal and/or nasal colonized mothers.

3. To study the efficacy of attempted decolonization in CA-MRSA colonized mothers in decreasing the incidence of transmission and development of SSTI and invasive infections in their infants during the first month of life.

Methods:

1. Vaginal and anterior nasal cultures will be obtained prospectively over several months from pregnant women who obtain their prenatal care through Obstetrical practices at Prentice Women's Hospital and Maternity Center of Northwestern Memorial Hospital during the time of GBS screening at 34-36 weeks gestation. Together, these practices account for 300-500 deliveries per month.

2. Cultures will be plated on blood agar and incubated at 37oC for 48 hours. S. aureus strains will be identified by colony morphology and latex agglutination. MRSA isolates will be identified by PCR or latex agglutination for penicillin binding protein 2a by detecting the mecA gene and clonality by PFGE. PCR testing will then be used to identify strains carrying the Panton-Valentine Leukocidin gene as a marker of virulence.

3. In a prospective case-control cohort study, newborns born to CA-MRSA colonized mothers will have anterior nares cultures for S. aureus obtained at birth and followed for the development of SSTI and invasive infections for one month. Samples positive for MRSA will be tested for similarities to maternal isolates through methods described above. The newborn incidence of MRSA infection will be compared between those born to non-colonized mothers and those born to colonized mothers.

4. In further stages of this study, women found to be nasally and/or vaginally colonized with CA-MRSA will be randomized to receive postpartum, either: 1) attempted decolonization with intranasal mupirocin with or without diluted chlorhexidine or Clorox baths or, 2) no intervention.

Potential Impact:

Understanding the epidemiology of the transmission dynamics of CA-MRSA in previously healthy neonates will provide important information to support the development of strategies aimed at the interruption of transmission and prevention of infection caused by CA-MRSA in this patient population, as well as in pregnant women. This will also allow for the development of infection control strategies in the hospital setting to prevent the spread of this organism among post-partum units and nurseries.


Recruitment information / eligibility

Status Recruiting
Enrollment 1500
Est. completion date January 2010
Est. primary completion date December 2009
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria:

- Healthy pregnant women who present for routine OB/GYN care during the of the 34-36 week gestation GBS screening visit.

- Healthy term and near-term infants born to these mothers

Exclusion Criteria:

- Pre-term infants

- Infants who had significant illness after birth, i.e. transferred to neonatal intensive care unit for significant illness.

Age limits for infants will be 0-4 weeks of age and both genders will be included.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention


Intervention

Other:
CA-MRSA Decolonization
In later stages of this study, women found to be nasally and/or vaginally colonized with CA-MRSA will be randomized to receive postpartum, either: 1) attempted decolonization with intranasal mupirocin twice a day for one to two weeks with or without diluted chlorhexidine or Clorox baths two to three times a week for one to two weeks or, 2) no intervention. The primary study is observational only.

Locations

Country Name City State
United States Prentice Women's Hospital and Maternity Center of Northwestern Memorial Hospital Chicago Illinois

Sponsors (3)

Lead Sponsor Collaborator
Ann & Robert H Lurie Children's Hospital of Chicago Northwestern Memorial Hospital, Thrasher Research Fund

Country where clinical trial is conducted

United States, 

References & Publications (4)

Crawford SE, Daum RS. Epidemic community-associated methicillin-resistant Staphylococcus aureus: modern times for an ancient pathogen. Pediatr Infect Dis J. 2005 May;24(5):459-60. Review. — View Citation

Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin Infect Dis. 2005 Feb 15;40(4):562-73. Epub 2005 Jan 24. Review. — View Citation

Fortunov RM, Hulten KG, Hammerman WA, Mason EO Jr, Kaplan SL. Community-acquired Staphylococcus aureus infections in term and near-term previously healthy neonates. Pediatrics. 2006 Sep;118(3):874-81. — View Citation

Kollef MH, Micek ST. Methicillin-resistant Staphylococcus aureus: a new community-acquired pathogen? Curr Opin Infect Dis. 2006 Apr;19(2):161-8. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary CA-MRSA vaginal and nasal colonization rates in pregnant women at the time of routine Group B Streptococcus (GBS) Screening at 34-36 week gestation visit. We will obtain vaginal and nasal samples at the 34-36 week gestation OB/Gyn visit. No
Primary The incidence of CA-MRSA skin, soft tissue and invasive (SSTI) infections in healthy term and near-term infants born to CA-MRSA colonized mothers. Infants born to CA-MRSA colonized mothers will be followed for CA-MRSA colonization and/or SSTIs for the first 4 weeks of life. No
Secondary In later stages of the study, we will study the efficacy of attempted decolonization in CA-MRSA colonized mothers in decreasing the incidence of transmission and development of SSTI and invasive infections in their infants during the first month of life. Infants born to CA-MRSA colonized moms will be followed for CA-MRSA colonization and/or SSTIs for the first 4 weeks of life. No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04210505 - Nasal Decolonization of Dialysis Patients Noses Phase 4
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Completed NCT02804711 - A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults Phase 1
Completed NCT02282605 - Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects Phase 1/Phase 2
Recruiting NCT06319235 - Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG® Phase 1/Phase 2
Enrolling by invitation NCT06317688 - Effectiveness of Highly Purified Anhydrous (HPA) Lanolin Versus Extra-Virgin Coconut Oil in Preventing Subacute Lactation Mastitis Phase 1
Withdrawn NCT02741869 - Photodisinfection for the Decolonization of Staphylococcus Aureus in Hemodialysis Patients N/A
Completed NCT03966040 - A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults Phase 1
Completed NCT04803708 - Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers Phase 1/Phase 2
Recruiting NCT05117398 - Dalbavancin Versus Standard Antibiotic Therapy for Catheter-related Bloodstream Infections Due to Staphylococcus Aureus Phase 3
Not yet recruiting NCT06456424 - Bacteriophage Therapy for Methicillin-Sensitive Staphylococcus Aureus Prosthetic Joint Infection Phase 1/Phase 2
Completed NCT02820883 - A Study of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults Phase 0
Active, not recruiting NCT01879761 - Immune Resolution After Staphylococcus Aureus Bacteremia
Completed NCT01375621 - Livestock Contact and MRSA in Rural Areas
Completed NCT04503252 - Probability of Target Attainment With Standard Intermittent Bolus Administration of Cefazolin in Patients With Complicated Infections Caused by Staphylococcus Aureus
Recruiting NCT06368856 - Pharmacology of Mupirocin in Nasal Application in Healthy Volunteers: Monocentric Study Phase 1
Not yet recruiting NCT05899140 - Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial Phase 4
Completed NCT01792804 - Staphylococcus Aureus Bacteremia Antibiotic Treatment Options Phase 3
Enrolling by invitation NCT04897971 - Serum Based Diagnosis of and Monitoring of Infection Recovery in Orthopedic Spine Implant Infections
Completed NCT00572910 - A Study to Evaluate the Safety and Immunogenicity of V710 in Adults With Kidney Disease on Hemodialysis (V710-005)(COMPLETED) Phase 2